Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC005654 | Panoply™ Human FCRL5 Knockdown Stable Cell Line | Inquiry |
| CSC-SC005654 | Panoply™ Human FCRL5 Over-expressing Stable Cell Line | Inquiry |
| CSC-RH0171M | Humanized FCRL5 Murine Tumor Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD06164Z | Human FCRL5 adenoviral particles | Inquiry |
| LV12764L | human FCRL5 (NM_001195388) lentivirus particles | Inquiry |
| LV12765L | human FCRL5 (NM_031281) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH055109 | shRNA set against Human FCRL5(NM_031281.2) | Inquiry |
| SHH055127 | shRNA set against Mouse Fcrl5(NM_183222.3) | Inquiry |
| SHH293873 | shRNA set against Human FCRL5 (NM_031281.2) | Inquiry |
| SHH293877 | shRNA set against Mouse FCRL5 (NM_183222.3) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFG019168 | Mouse Fcrl5 cDNA Clone(NM_001113238.1) | Inquiry |
| CDFL004608 | Mouse Fcrl5 cDNA Clone(NM_183222.3) | Inquiry |
| MiUTR1H-03601 | FCRL5 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-04658 | FCRL5 miRNA 3'UTR clone | Inquiry |
| CDCB182664 | Rabbit FCRL5 ORF clone (XM_008264266.1) | Inquiry |
| CDCL107717 | Mouse FCRL5 ORF clone (NM_001195388.1) | Inquiry |
| CDCL107723 | Human Fcrl5 ORF clone (NM_001113238.1) | Inquiry |
| CDCL150756 | Mouse Fcrl5 ORF clone (NM_183222.3) | Inquiry |
| CDCS409325 | Human FCRL5 ORF Clone (BC101067) | Inquiry |
The FCRL5 gene, located on human chromosome 1q21–1q22, is an important member of the Fc receptor-like (FCRL) family within the immunoglobulin superfamily. This gene cluster includes multiple FCRL genes, reflecting an evolutionary history likely shaped by gene duplication events. FCRL5 encodes a type I transmembrane protein whose extracellular region contains up to eight immunoglobulin-like C2-type domains, suggesting its involvement in recognizing diverse ligands and mediating complex intercellular interactions. Unlike classical Fc receptors, FCRL5 lacks canonical motifs for high-affinity binding to immunoglobulin constant regions, classifying it as an "orphan receptor", and its specific endogenous ligands remain under investigation. Expression of FCRL5 is highly lineage-specific, largely restricted to B lymphocytes at different developmental stages, from early B cell precursors to mature B cell subsets, particularly marginal zone B cells and plasma cells, with dynamic expression levels. Alternative splicing produces multiple transcript variants encoding distinct protein isoforms, adding further complexity and diversity to its functional regulation.
FCRL5 functions as a dual regulator of B cell receptor (BCR) signaling, integrating microenvironmental cues and co-receptor engagement to fine-tune B cell responses to antigens. In the absence of co-stimulatory signals, its intracellular domain contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs). When recruited near the BCR signaling complex, ITIMs can be phosphorylated by Src-family kinases, leading to recruitment and activation of phosphatases such as SHP-1, which dephosphorylate key BCR signaling components, thereby dampening B cell activation. Conversely, when B cells receive co-stimulation through complement receptor 2 (CR2), FCRL5 switches function: it cooperates with CR2 to produce calcium responses stronger than BCR or BCR+CR2 stimulation alone, promoting full B cell activation, proliferation, immunoglobulin class switching, and plasma cell differentiation. This makes FCRL5 a "molecular switch", acting as a brake or accelerator depending on the immune context. Such precise modulation is critical for maintaining humoral immune balance, preventing inappropriate B cell activation under basal conditions while amplifying protective antibody responses when necessary.
Figure 1. Regulation of BCR signaling and B-cell function by FCRLs. (Rostamzadeh D, et al., 2018)
Clinically, FCRL5 has significance as a biomarker and potential immunotherapy target in B cell malignancies. Aberrant high expression is observed in multiple B cell lymphomas and leukemias, particularly hairy cell leukemia and certain subtypes of chronic lymphocytic leukemia, making it a valuable tool for tumor subclassification and minimal residual disease monitoring. Its surface-specific expression and role in promoting B cell survival and proliferation have spurred the development of antibody-drug conjugates (ADCs) and bispecific antibodies targeting FCRL5, currently in preclinical or early clinical development. These strategies aim to selectively deliver cytotoxic agents or T cell effector activity to FCRL5-expressing malignant B cells, achieving precision targeting while minimizing off-target effects.
In autoimmune diseases, although research is preliminary, dysregulation of FCRL5 signaling may contribute to pathologic autoantibody production, suggesting that modulating its activity could help restore B cell tolerance. Challenges remain, including identifying endogenous ligands, clarifying whether FCRL5 primarily mediates inhibitory or activating signals under different pathological states, and ensuring that targeted therapies do not disrupt normal B cell subsets critical for immune function. Overall, FCRL5 is a functionally complex, B cell-specific regulatory molecule, evolving from a subject of basic immunology research to a promising novel target in tumor immunotherapy.
References